Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-6 Sublingual Tablets in Acute Perforating Artery Infarction
NCT07721545Phase 3Not yet recruiting
- Sponsor
- NeuroDawn
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lacunar infarct (LI) comparing Y-6 tablet with Placebo (2 arms). Primary endpoint: Proportion of participants achieving a modified Rankin Scale score <=1 at 90 days. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
cilostazol + dexborneol
03
Conditions
Lacunar infarct (LI)
Beyond the preview
Go deeper on NCT07721545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07721545.